Publications by authors named "Tomoaki Yamanoi"
Article Synopsis
- - This study compared the clinical outcomes of robot-assisted partial nephrectomy (RAPN) and image-guided percutaneous cryoablation (IG-PCA) in patients with clinical T1 renal cell carcinoma over a period from 2012 to 2021, analyzing data from 679 patients.
- - After matching for baseline characteristics, 108 patients from each treatment group showed that while RAPN had no local recurrences, IG-PCA had three cases of tumor progression, which were successfully treated with additional thermal ablations.
- - Overall, both treatments had similar long-term survival rates, complication rates, and renal function preservation, indicating that IG-PCA can provide oncological outcomes that are comparable to RAPN.
Article Synopsis
- Immune checkpoint inhibitor (ICI) combination therapies are standard treatments for metastatic renal cell carcinoma (mRCC), but there are limited comparative studies using real-world data to assess their effectiveness.
- The study analyzed records from 320 clear cell RCC patients to compare outcomes between those treated with ICI+ICI versus ICI+tyrosine kinase inhibitor (TKI) combinations.
- Results showed that while overall survival was similar for both treatments, the progression-free survival was significantly longer for ICI+TKI, and patients on ICI+ICI had a higher rate of progressive disease, although treatment-related side effects varied between the two groups.
Introduction: Concomitant medications can affect the efficacy of immune checkpoint inhibitors. The association between histamine-2 receptor antagonists (H2RAs), major antacids similar to proton pump inhibitors (PPIs), and the efficacy of pembrolizumab for metastatic urothelial carcinoma (mUC) treatment has been poorly evaluated. We evaluated the impact of PPIs and H2RAs on oncological outcomes in mUC patients treated with pembrolizumab.
View Article and Find Full Text PDFThis review presents the latest insights on robot-assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally.
View Article and Find Full Text PDFOne-third of renal cell carcinomas (RCCs) without metastases develop metastatic disease after extirpative surgery for the primary tumors. The majority of metastatic RCC cases, along with treated primary lesions, involve limited lesions termed "oligo-recurrent" disease. The role of metastasis-directed therapy (MDT), including stereotactic body radiation therapy (SBRT) and metastasectomy, in the treatment of oligo-recurrent RCC has evolved.
View Article and Find Full Text PDFPurpose: Radiological tumor burden has been reported to be prognostic in many malignancies in the immunotherapy era, yet whether it is prognostic in patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab remains uninvestigated. We sought to assess the predictive and prognostic value of radiological tumor burden in patients with mUC.
Methods: We performed a retrospective analysis of 308 patients with mUC treated with pembrolizumab.